Total Payments
$552.45
2024 Payments
$125.00
Companies
11
Transactions
16
Medicare Patients
1,792
Medicare Billing
$373,061
Payment Breakdown by Category
Food & Beverage$552.45 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $552.45 | 16 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $142.62 | 2 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $110.70 | 2 | $0 (2022) |
| Dendreon Pharmaceuticals LLC | $65.16 | 1 | $0 (2023) |
| Gilead Sciences, Inc. | $63.55 | 4 | $0 (2018) |
| AbbVie Inc. | $62.79 | 1 | $0 (2021) |
| Puma Biotechnology, Inc. | $23.77 | 1 | $0 (2020) |
| Blue Earth Diagnostics Limited | $20.46 | 1 | $0 (2018) |
| Exelixis Inc. | $17.52 | 1 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $16.71 | 1 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $16.55 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $125.00 | 1 | E.R. Squibb & Sons, L.L.C. ($125.00) |
| 2023 | $81.71 | 2 | Dendreon Pharmaceuticals LLC ($65.16) |
| 2022 | $20.06 | 1 | Novartis Pharmaceuticals Corporation ($20.06) |
| 2021 | $62.79 | 1 | AbbVie Inc. ($62.79) |
| 2020 | $41.39 | 2 | Puma Biotechnology, Inc. ($23.77) |
| 2019 | $108.16 | 2 | Novartis Pharmaceuticals Corporation ($90.64) |
| 2018 | $62.73 | 4 | Gilead Sciences, Inc. ($25.56) |
| 2017 | $50.61 | 3 | Gilead Sciences Inc ($37.99) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Oncology | ||||||
| 10/09/2023 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $65.16 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 08/29/2023 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/23/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: ONCOLOGY | ||||||
| 09/15/2021 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $62.79 | General |
| Category: ONCOLOGY | ||||||
| 08/20/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.62 | General |
| Category: Oncology | ||||||
| 06/29/2020 | Puma Biotechnology, Inc. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $23.77 | General |
| Category: ONCOLOGY | ||||||
| 08/27/2019 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), PIQRAY | Food and Beverage | In-kind items and services | $90.64 | General |
| Category: ONCOLOGY | ||||||
| 07/15/2019 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $17.52 | General |
| Category: Oncology | ||||||
| 10/30/2018 | Blue Earth Diagnostics Limited | Axumin (Drug) | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: Diagnostic Imaging | ||||||
| 05/11/2018 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $11.03 | General |
| Category: HCV | ||||||
| 03/13/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: ONCOLOGY | ||||||
| 02/21/2018 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $14.53 | General |
| Category: HCV | ||||||
| 10/10/2017 | Gilead Sciences Inc | Epclusa (Drug) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: HCV | ||||||
| 08/03/2017 | Gilead Sciences Inc | Harvoni (Drug) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: HCV | ||||||
| 03/29/2017 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $12.62 | General |
| Category: Anemia | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 480 | 1,015 | $142,712 | $86,715 |
| 2022 | 9 | 462 | 1,045 | $151,433 | $95,141 |
| 2021 | 9 | 493 | 1,194 | $173,836 | $112,306 |
| 2020 | 9 | 357 | 934 | $140,936 | $78,898 |
Total Patients
1,792
Total Services
4,188
Medicare Billing
$373,061
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 161 | 542 | $79,036 | $50,291 | 63.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 176 | 267 | $26,517 | $16,679 | 62.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 40 | 59 | $14,061 | $7,562 | 53.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $6,341 | $3,333 | 52.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 23 | 53 | $5,587 | $3,174 | 56.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 23 | 25 | $5,367 | $2,463 | 45.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $3,876 | $2,122 | 54.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 17 | 29 | $1,927 | $1,092 | 56.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 161 | 599 | $84,904 | $56,122 | 66.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 147 | 239 | $23,062 | $15,491 | 67.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 46 | 75 | $17,317 | $9,836 | 56.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 19 | 19 | $5,487 | $3,053 | 55.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 24 | 24 | $5,548 | $2,910 | 52.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 15 | 27 | $3,964 | $2,093 | 52.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 13 | 14 | $4,057 | $2,085 | 51.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 20 | 20 | $4,224 | $2,049 | 48.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 28 | $2,870 | $1,502 | 52.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 165 | 705 | $98,700 | $67,635 | 68.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 123 | 223 | $21,185 | $14,655 | 69.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 50 | 82 | $18,696 | $11,079 | 59.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 35 | 39 | $11,076 | $5,939 | 53.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 30 | 30 | $6,750 | $3,539 | 52.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 38 | 55 | $5,555 | $3,007 | 54.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 14 | 14 | $3,990 | $2,341 | 58.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 20 | 20 | $4,140 | $2,068 | 50.0% |
About Dr. Erin Ezzell, D.O
Dr. Erin Ezzell, D.O is a Hematology & Oncology healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1801091996.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Erin Ezzell, D.O has received a total of $552.45 in payments from pharmaceutical and medical device companies, with $125.00 received in 2024. These payments were reported across 16 transactions from 11 companies. The most common payment nature is "Food and Beverage" ($552.45).
As a Medicare-enrolled provider, Ezzell has provided services to 1,792 Medicare beneficiaries, totaling 4,188 services with total Medicare billing of $373,061. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Internal Medicine
- Location Oklahoma City, OK
- Active Since 06/19/2007
- Last Updated 07/03/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1801091996
Products in Payments
- OPDIVO (Biological) $142.62
- KISQALI (Drug) $110.70
- PROVENGE (Drug) $65.16
- VENCLEXTA (Drug) $62.79
- Epclusa (Drug) $44.66
- NERLYNX (Drug) $23.77
- Axumin (Drug) $20.46
- Harvoni (Drug) $18.89
- Cabometyx (Drug) $17.52
- KEYTRUDA (Biological) $16.71
- XARELTO (Drug) $16.55
- INJECTAFER (Drug) $12.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Oklahoma City
Robert Reynolds, Md, MD
Hematology & Oncology — Payments: $14,579
Hematology & Oncology $14,579
Philip Comp, Md, MD
Hematology & Oncology — Payments: $13,151
Hematology & Oncology $13,151
Dr. Charles Hollen, M.d, M.D
Hematology & Oncology — Payments: $12,135
Hematology & Oncology $12,135
Jennifer Holter-Chakrabarty, Md, MD
Hematology & Oncology — Payments: $11,994
Hematology & Oncology $11,994
Dr. Saadia Chohan, Md, MD
Hematology & Oncology — Payments: $11,197
Hematology & Oncology $11,197
Abby Bova, Md, MD
Hematology & Oncology — Payments: $5,791
Hematology & Oncology $5,791